Video

Urology Times 50 Innovations Series: LHRH analogues in prostate cancer

Author(s):

Urology Times staff

“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.

As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Vanita Gaglani, RPT, answers a question during a video interview
Man talking with doctor | Image Credit: © DragonImages - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Related Content
Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC
March 4th 2025

Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC

Hannah Clarke
The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Enrollment goal met in trial of Vanquish device for localized prostate cancer
February 27th 2025

Enrollment goal met in trial of Vanquish device for localized prostate cancer

Hannah Clarke
Data from the VAPOR 2 trial are intended to support a submission to the FDA for 510(k) clearance of the device.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC
February 24th 2025

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Hannah Clarke
The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor
Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.
© 2025 MJH Life Sciences

All rights reserved.